Login to Your Account

Trimeris Back to Square One as Arigene Buyout Collapses

By Jennifer Boggs

Wednesday, December 30, 2009
A lack of funds have put the kibosh on Arigene Co. Ltd.'s planned acquisition of troubled Trimeris Inc., leaving the Durham, N.C.-based firm to seek out other strategic moves as it faces decreasing sales of HIV drug Fuzeon (enfuvirtide). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription